Corporate Overview

Momenta is a biotechnology company with a validated innovative disease analytics platform. Our scientific foundation is a set of tools and methods that allow us to develop a deep understanding of the links between a compound’s chemical structure, biological function and its manufacturing process. We are applying our innovative technology to the discovery and development of novel therapeutics for immune-mediated diseases with high unmet need.  Momenta also has a focused pipeline of two biosimilar candidates: M923, Momenta’s wholly-owned proposed biosimilar to HUMIRA^®, and M710, a proposed biosimilar to EYLEA^® being developed in collaboration with Mylan.  

• In 2010, we validated our approach to the development of highly complex molecules by becoming the first company to achieve U.S. regulatory approval of a generic version of LOVENOX^® (enoxaparin sodium injection) for the treatment of deep vein thrombosis (DVT).
• In 2015, we and Sandoz received U.S. regulatory approval for and launched our second complex generic, Glatopa^®  20 mg (glatiramer acetate injection), a fully substitutable generic version of daily COPAXONE^® 20 mg.  Glatopa 20 mg was the first approved generic drug available for the treatment of patients with relapsing-forms of multiple sclerosis.
• In 2018, we and Sandoz received FDA approval of their Abbreviated New Drug Application for a three times weekly COPAXONE^® 40mg/mL (glatiramer acetate injection).
• Today, Momenta’s development pipeline  is focused on discovering and developing novel therapeutics to treat rare, immune-mediated diseases. Momenta’s goal is to continue pushing our science forward to develop products that create value for patients, our healthcare system and our shareholders.

LOVENOX^® is a registered trademark of Sanofi-Aventis. COPAXONE^® is a registered trademark of Teva Pharmaceutical Industries Ltd. Glatopa^® is a registered trademark of Novartis AG. Enoxaparin Sodium Injection and Glatopa^™ were developed under a collaboration agreement between Momenta and Sandoz. Both products are marketed under the Sandoz brand.. EYLEA® (aflibercept)  is a registered trademark of Regeneron Pharmaceuticals, Inc.

Last Updated 11/7/18